<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59PM UTC 2026-07-30--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:currency="http://xbrl.sec.gov/currency/2026" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2026" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2026" xmlns:sdev="http://www.novabaypharma.com/20260630" xmlns:sic="http://xbrl.sec.gov/sic/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:stpr="http://xbrl.sec.gov/stpr/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-types="http://fasb.org/us-types/2026" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novabaypharma.com/20260630">
  <xsd:import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2026" schemaLocation="https://xbrl.sec.gov/exch/2026/exch-2026.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2026" schemaLocation="https://xbrl.sec.gov/currency/2026/currency-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2026" schemaLocation="https://xbrl.sec.gov/naics/2026/naics-2026.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2026" schemaLocation="https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2026" schemaLocation="https://xbrl.sec.gov/sic/2026/sic-2026.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdev-20260630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdev-20260630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdev-20260630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sdev-20260630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.novabaypharma.com/20260630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.novabaypharma.com/20260630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.novabaypharma.com/20260630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-unaudited" roleURI="http://www.novabaypharma.com/20260630/role/statement-condensed-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited" roleURI="http://www.novabaypharma.com/20260630/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.novabaypharma.com/20260630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-1-organization">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-fair-value-measurements" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-3-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-prepaid-expenses-and-other-current-assets" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-4-prepaid-expenses-and-other-current-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-5-digital-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Digital Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-liabilities" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-6-accrued-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-and-contingencies" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-7-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-financing-activities" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-8-financing-activities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Financing Activities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-convertible-notes" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-9-convertible-notes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Convertible Notes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-common-stock-warrants-and-warrant-liabilities" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-10-common-stock-warrants-and-warrant-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Common Stock Warrants and Warrant Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity-deficit" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-11-stockholders-equity-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-12-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-divestitures" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-13-divestitures">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Divestitures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-14-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-related-party-transactions" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-15-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 15 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-subsequent-events" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-16-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 16 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.novabaypharma.com/20260630/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995445 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995446 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-fair-value-measurements-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-3-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995447 - Disclosure - Note 3 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-prepaid-expenses-and-other-current-assets-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995448 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-5-digital-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995449 - Disclosure - Note 5 - Digital Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-liabilities-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-6-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995450 - Disclosure - Note 6 - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-and-contingencies-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-7-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995451 - Disclosure - Note 7 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-common-stock-warrants-and-warrant-liabilities-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-10-common-stock-warrants-and-warrant-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995452 - Disclosure - Note 10 - Common Stock Warrants and Warrant Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-12-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995453 - Disclosure - Note 12 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-divestitures-tables" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-13-divestitures-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995454 - Disclosure - Note 13 - Divestitures (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-1-organization-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995455 - Disclosure - Note 1 - Organization (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995456 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995457 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995458 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995459 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-fair-value-measurements-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-3-fair-value-measurements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995460 - Disclosure - Note 3 - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995461 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995462 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-5-digital-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995463 - Disclosure - Note 5 - Digital Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-crypto-asset-holding-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-5-digital-assets-crypto-asset-holding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995464 - Disclosure - Note 5 - Digital Assets - Crypto Asset, Holding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-digital-assets-crypto-asset-activity-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-5-digital-assets-crypto-asset-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Note 5 - Digital Assets - Crypto Asset, Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-liabilities-summary-of-accrued-liabilities-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-6-accrued-liabilities-summary-of-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 6 - Accrued Liabilities - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-and-contingencies-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-7-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-and-contingencies-lease-expense-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-7-commitments-and-contingencies-lease-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 7 - Commitments and Contingencies - Lease Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-financing-activities-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-8-financing-activities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 8 - Financing Activities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-convertible-notes-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-9-convertible-notes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 9 - Convertible Notes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-common-stock-warrants-and-warrant-liabilities-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-10-common-stock-warrants-and-warrant-liabilities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 10 - Common Stock Warrants and Warrant Liabilities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 10 - Common Stock Warrants and Warrant Liabilities - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details-parentheticals" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 10 - Common Stock Warrants and Warrant Liabilities - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-common-stock-warrants-and-warrant-liabilities-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-10-common-stock-warrants-and-warrant-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Note 10 - Common Stock Warrants and Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockholders-equity-deficit-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-11-stockholders-equity-deficit-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 11 - Stockholders' Equity (Deficit) (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-12-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 12 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 12 - Stock-based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-divestitures-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-13-divestitures-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 13 - Divestitures (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-divestitures-discontinued-operations-details" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-13-divestitures-discontinued-operations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 13 - Divestitures - Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-14-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 14 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-related-party-transactions-details-textual" roleURI="http://www.novabaypharma.com/20260630/role/statement-note-15-related-party-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 15 - Related Party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sdev_AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase" name="AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_AtTheMarketOfferingAgreementMember" name="AtTheMarketOfferingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_AvenovaAssetsMember" name="AvenovaAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_CashAndCashEquivalentsIncludingDisposalGroup" name="CashAndCashEquivalentsIncludingDisposalGroup" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ClassOfWarrantOrRightExpiredDuringPeriod" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ClassOfWarrantOrRightNumberOfSecuritiesWithholding" name="ClassOfWarrantOrRightNumberOfSecuritiesWithholding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ClassOfWarrantsOrRightsReclassifiedFromLiabilityToEquity" name="ClassOfWarrantsOrRightsReclassifiedFromLiabilityToEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ComissionPercent" name="ComissionPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CommonStockAvailableForIssuance" name="CommonStockAvailableForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ConversionOfUnsecuredConvertibleNotesToCommonStockMember" name="ConversionOfUnsecuredConvertibleNotesToCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_CryptoAssetAcquiredThroughExchange" name="CryptoAssetAcquiredThroughExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_CryptoAssetNumberOfUnitsAcquired" name="CryptoAssetNumberOfUnitsAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CryptoAssetNumberOfUnitsAcquiredThroughExchange" name="CryptoAssetNumberOfUnitsAcquiredThroughExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CryptoAssetNumberOfUnitsDisposedOf" name="CryptoAssetNumberOfUnitsDisposedOf" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CryptoAssetNumberOfUnitsReceivedAsRewards" name="CryptoAssetNumberOfUnitsReceivedAsRewards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_CryptoAssetNumberOfUnitsReceivedFromEquityIssuance" name="CryptoAssetNumberOfUnitsReceivedFromEquityIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CryptoAssetPerTokenPrice" name="CryptoAssetPerTokenPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CryptoAssetPercentOfTotalSupply" name="CryptoAssetPercentOfTotalSupply" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_CryptoAssetReceivedFromEquityIssuance" name="CryptoAssetReceivedFromEquityIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_CryptoAssetReceviedAsRewards" name="CryptoAssetReceviedAsRewards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_CryptoAssetStakingAward" name="CryptoAssetStakingAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_DigitalAssetsPolicyTextBlock" name="DigitalAssetsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_DigitalAssetsReceivedInExchangeForPreFundedWarrants" name="DigitalAssetsReceivedInExchangeForPreFundedWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense" name="DisposalGroupIncludingDiscontinuedOperationSellingAndMarketingExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_ElectionOfTheHolderPriorToTheDateOfIssuanceMember" name="ElectionOfTheHolderPriorToTheDateOfIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_EquityIssuableMaximumOfferingPrice" name="EquityIssuableMaximumOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sdev_EquityOfferingPeriodForRightToConsentModificationOfDigitalAssetStrategy" name="EquityOfferingPeriodForRightToConsentModificationOfDigitalAssetStrategy" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_EquityOfferingRightToConsentModificationOfDigitalAssetStrategyPercentageOfOriginalPurchaseOwned" name="EquityOfferingRightToConsentModificationOfDigitalAssetStrategyPercentageOfOriginalPurchaseOwned" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_FairValueOfWarrantsExercised" name="FairValueOfWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_FairValueOfWarrantsIssued" name="FairValueOfWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_FrameworkMember" name="FrameworkMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_IncentiveStockOptionsISOMember" name="IncentiveStockOptionsISOMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_January2026PrivatePlacementMember" name="January2026PrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_January2026SKYTokensMember" name="January2026SKYTokensMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_June2024WarrantMember" name="June2024WarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_LeaseTerminationFee" name="LeaseTerminationFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sdev_LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent" name="LossIncomeFromDiscontinuedOperationsNetOfTaxAttributableToParent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_MaximumPercentageOfCommonStockOutstanding" name="MaximumPercentageOfCommonStockOutstanding" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_MonthlyConsultingFee" name="MonthlyConsultingFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sdev_NeutrophaseMember" name="NeutrophaseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_NoncashGainLossOnWarrantLiabilitiesInExcessOfProceedsAtIssuance" name="NoncashGainLossOnWarrantLiabilitiesInExcessOfProceedsAtIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_October2025PreFundedWarrantsMember" name="October2025PreFundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_OfficeSpaceForCorporateHeadquartersInEmeryvilleCaliforniaMember" name="OfficeSpaceForCorporateHeadquartersInEmeryvilleCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_OperatingLeaseLiabilityDerecognized" name="OperatingLeaseLiabilityDerecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_OwnershipPercentage" name="OwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_PaymentForConsultingFees" name="PaymentForConsultingFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_PercentOfClosingPrice" name="PercentOfClosingPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sdev_PerformanceBasedRSUsMember" name="PerformanceBasedRSUsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_PolicyTable" name="PolicyTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_PrefundedWarrantsIssuedDuringPeriod" name="PrefundedWarrantsIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ProceedsFromIssuanceOrSaleOfEquityNet" name="ProceedsFromIssuanceOrSaleOfEquityNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ProfessionalServicesPayableCurrent" name="ProfessionalServicesPayableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sdev_R01Member" name="R01Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ReclassifyPrivatePlacementWarrants" name="ReclassifyPrivatePlacementWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure" name="RestrictedCashHeldAsACertificateOfDepositFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sdev_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_SKYTokensAndStablecoinsMember" name="SKYTokensAndStablecoinsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_SKYTokensMember" name="SKYTokensMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" name="ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_September2022WarrantsMember" name="September2022WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_SeriesBPreferredStockPostsplitMember" name="SeriesBPreferredStockPostsplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_SeriesF1WarrantsMember" name="SeriesF1WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_SeriesF3WarrantsMember" name="SeriesF3WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingCommonStock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentageOfStockOwnedByShareholderMinimum" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFirstThresholdValue" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsFirstThresholdValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSecondThresholdValue" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSecondThresholdValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsThirdThresholdValue" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsThirdThresholdValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVolumeWeightedAveragePriceThresholdOne" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVolumeWeightedAveragePriceThresholdOne" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVolumeWeightedAveragePriceThresholdThree" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVolumeWeightedAveragePriceThresholdThree" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVolumeWeightedAveragePriceThresholdTwo" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVolumeWeightedAveragePriceThresholdTwo" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sdev_ShareholderOfMoreThan10PercentMember" name="ShareholderOfMoreThan10PercentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_StablecoinsMember" name="StablecoinsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_StakingAwardSKYTokensMember" name="StakingAwardSKYTokensMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_StockIssuedInConnectionWithExerciseOfWarrantsShares" name="StockIssuedInConnectionWithExerciseOfWarrantsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_StockIssuedInConnectionWithExerciseOfWarrantsValue" name="StockIssuedInConnectionWithExerciseOfWarrantsValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" name="StockholdersEquityNoteWarrantsOrRightsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TLFBioInnovationWarrantsMember" name="TLFBioInnovationWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_The2007OmnibusIncentivePlanMember" name="The2007OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_The2017OmnibusIncentivePlanMember" name="The2017OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_The2021PrivatePlacementProgramMember" name="The2021PrivatePlacementProgramMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_The2024WarrantRepriceTransactionMember" name="The2024WarrantRepriceTransactionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_The2026EquityIncentivePlanMember" name="The2026EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_The2026PlanMember" name="The2026PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheDecember2023WarrantsMember" name="TheDecember2023WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheJanuary2026WarrantsMember" name="TheJanuary2026WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheJuly2020WarrantsMember" name="TheJuly2020WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheJuly2024SeriesF1AndF3WarrantsMember" name="TheJuly2024SeriesF1AndF3WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheJuly2024SeriesF1WarrantsMember" name="TheJuly2024SeriesF1WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheNovember2021WarrantsMember" name="TheNovember2021WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheNovember2022A1WarrantsMember" name="TheNovember2022A1WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TheOctober2025AndJanuary2026PreFundedWarrantsMember" name="TheOctober2025AndJanuary2026PreFundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_TimeBasedRSUsMember" name="TimeBasedRSUsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_USDSTokensMember" name="USDSTokensMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_USDTAndUSDSTokensMember" name="USDTAndUSDSTokensMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_USDTTokensMember" name="USDTTokensMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_UnsecuredConvertibleNotesMember" name="UnsecuredConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_VWAPRSUsMember" name="VWAPRSUsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_WarrantLiabilitiesFairValueDisclosure" name="WarrantLiabilitiesFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sdev_WarrantLiabilitiesPolicyTextBlock" name="WarrantLiabilitiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_WarrantsAndPrefundedWarrantsMember" name="WarrantsAndPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sdev_WarrantsExercisableAtNinthMonthsPercentage" name="WarrantsExercisableAtNinthMonthsPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_WarrantsExercisableAtSixMonthsPercentage" name="WarrantsExercisableAtSixMonthsPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_WarrantsExercisableAtTwelveMonthsPercentage" name="WarrantsExercisableAtTwelveMonthsPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sdev_WarrantsExercisedOnCashlessBasis" name="WarrantsExercisedOnCashlessBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sdev_WarrantsIssuedReverseStockSplit" name="WarrantsIssuedReverseStockSplit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sdev_WoundCareMember" name="WoundCareMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-details" name="statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" name="statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details-parentheticals" name="statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-schedule-of-stockholders-equity-note-warrants-or-rights-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-tables" name="statement-statement-note-10-common-stock-warrants-and-warrant-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details" name="statement-statement-note-12-stockbased-compensation-schedule-of-nonvested-restricted-stock-units-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-12-stockbased-compensation-tables" name="statement-statement-note-12-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-13-divestitures-discontinued-operations-details" name="statement-statement-note-13-divestitures-discontinued-operations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-13-divestitures-discontinued-operations-details5AB62A2A-3D69-44C4-89B6-C9C38E358B73" name="statement-statement-note-13-divestitures-discontinued-operations-details5AB62A2A-3D69-44C4-89B6-C9C38E358B73" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-13-divestitures-discontinued-operations-details6EF4B66A-AEF3-41E8-BD4D-91986D0DF134" name="statement-statement-note-13-divestitures-discontinued-operations-details6EF4B66A-AEF3-41E8-BD4D-91986D0DF134" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-13-divestitures-tables" name="statement-statement-note-13-divestitures-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-cash-cash-equivalents-restricted-cash-and-restricted-cash-equivalents-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-schedule-of-earnings-per-share-basic-and-diluted-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" name="statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details400762DC-629D-4269-AD74-82AEFADFB7AC" name="statement-statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details400762DC-629D-4269-AD74-82AEFADFB7AC" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-3-fair-value-measurements-tables" name="statement-statement-note-3-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" name="statement-statement-note-4-prepaid-expenses-and-other-current-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-5-digital-assets-crypto-asset-activity-details" name="statement-statement-note-5-digital-assets-crypto-asset-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-5-digital-assets-crypto-asset-holding-details" name="statement-statement-note-5-digital-assets-crypto-asset-holding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-5-digital-assets-tables" name="statement-statement-note-5-digital-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-6-accrued-liabilities-summary-of-accrued-liabilities-details" name="statement-statement-note-6-accrued-liabilities-summary-of-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-6-accrued-liabilities-tables" name="statement-statement-note-6-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-7-commitments-and-contingencies-lease-expense-details" name="statement-statement-note-7-commitments-and-contingencies-lease-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-7-commitments-and-contingencies-lease-expense-detailsD1D6E157-6919-462E-80E5-4FEC6FC86CF4" name="statement-statement-note-7-commitments-and-contingencies-lease-expense-detailsD1D6E157-6919-462E-80E5-4FEC6FC86CF4" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-note-7-commitments-and-contingencies-tables" name="statement-statement-note-7-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sdev_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
